A5044107490- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Extracellular vesicles in disease
- Immune Cell Function and Interaction
- MicroRNA in disease regulation
- Sarcoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Circular RNAs in diseases
- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Cancer-related molecular mechanisms research
- T-cell and Retrovirus Studies
- Lung Cancer Research Studies
- Reproductive System and Pregnancy
- Cancer Immunotherapy and Biomarkers
- Ubiquitin and proteasome pathways
- Cancer-related gene regulation
- Galectins and Cancer Biology
- Monoclonal and Polyclonal Antibodies Research
- RNA modifications and cancer
- Peptidase Inhibition and Analysis
University of Padua
2016-2025
Città della Speranza Foundation
2015-2024
Azienda Ospedaliera di Padova
2007-2023
Université Paris-Sud
2015
Centre National pour la Recherche Scientifique et Technique (CNRST)
2015
Institut Gustave Roussy
2015
Institut Necker Enfants Malades
2015
Université Paris Cité
2015
Roche (Switzerland)
2015
Merck Serono (Switzerland)
2015
Anaplastic lymphoma kinase (ALK)-positive lymphomas respond to chemotherapy, but relapses, which bear a poor prognosis, occur. Crizotinib inhibits ALK in vitro and vivo was administered as monotherapy 11 ALK+ patients who were resistant/refractory cytotoxic therapy. The overall response rate 10 of (90.9%; 95% confidence interval [CI] = 58.7% 99.8%). Disease status at the latest follow-up is follows: four are complete (CR) (months >21, >30, >35, >40) under continuous crizotinib...
Significance The majority of non-Hodgkin B-cell lymphomas arise from the malignant transformation germinal center B cells. molecular pathogenesis these malignancies is not fully understood. Although a number oncogenes and tumor suppressors have been identified among protein-coding genes, role microRNAs during lymphomagenesis remains largely unexplored. Our results identify for microRNA 28 (miR-28) in normal These data provide new insights on microRNA-mediated posttranscriptional regulation...
With the aim of describing long-term follow-up and to define prognostic role clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up 22 years homogeneously treated within international ALCL99 trial. The 10-year progression free survival (PFS) was 70% overall 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological...
Extracellular vesicles (EVs) are rapidly gaining in popularity as biomarkers of various diseases, acting cargoes valuable information from the cell origin. Despite their important value, current use clinical practice is still limited. Among limiting factors, one most critical challenges regarding isolation. In fact, conventional approaches characterized by low purity and throughput, or poor reproducibility. Here, we present a droplet microfluidic platform specifically developed for EV...
Plasma exosomal microRNAs (miRNAs) are considered as valid circulating biomarkers for cancer diagnosis and prognosis. Quantitative real-time polymerase chain reaction (qRT-PCR), the most commonly used technique to assess miRNA levels, requires a normalization step involving uniformly expressed endogenous miRNAs. However, there is still no consensus on reference miRNAs plasma abundance normalization. In this study, we identified panel of with stable by analyzing public exosome RNA-seq data...
Abstract T‐cell acute lymphoblastic leukemia (T‐ALL) and lymphoma (T‐LBL) share common morphological immunophenotypic features are treated with similar therapeutic approaches. Nonetheless, they show distinct clinical presentations, suggesting that may represent two different biological entities. To investigate the genetic characteristics of T‐LBL T‐ALL, we used genomic transcriptional profiling Genome‐wide gene expression profiling, performed on 20 10 T‐ALL diagnostic specimens, revealed...
Extracellular circulating DNA (cfDNA) can be found in small amounts plasma of healthy individuals. Increased levels cfDNA have been reported patients with cancer breast, cervix, colon, liver and it was shown that originate from both tumour non-tumour cells.Levels a large series children lymphoma were evaluated analyzed relation clinical characteristics.plasma obtained at diagnosis 201 paediatric [43 Hodgkin lymphomas (HL), 45 anaplastic cell (ALCL), 88 Burkitt (BL), 17 lymphoblastic (LBL), 8...
Burkitt lymphoma (BL) and Diffuse Large B-Cell Lymphoma (DLBCL) account for most cases of non-Hodgkin (NHL) in childhood. We report the clinical characteristics, outcome prognostic factors children with BL or DLBCL treated according to Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) LNH-97 protocol. Patients aged up 18 years that were newly diagnosed BL/DLBCL included study. Therapy consisted pre-phase followed by 2-6 high-dose chemotherapy courses tailored lactate...
Minimal residual disease (MRD) is the most powerful prognostic factor in pediatric acute lymphoblastic leukemia (ALL). Real-time quantitative polymerase chain reaction (RQ-PCR) represents gold standard for molecular MRD assessment and risk-based stratification of front-line treatment. In protocols Italian Association Pediatric Hematology Oncology (AIEOP) Berlin-Frankfurth-Munschen (BFM) group AIEOP-BFM ALL2009 ALL2017, B-lineage ALL patients with high RQ-PCR-MRD at day+33 positive day+78 are...
Monoallelic and biallelic mutations of the PRF1 gene have been reported in some cases childhood lymphoma. Anaplastic large cell lymphoma (ALCL) accounts for 10% to 15% all lymphomas. To assess possible role ALCL, authors screened a series patients collected by Associazione Italiana di Ematologia Oncologia Pediatrica (AIEOP).The investigated 44 with ALCL direct sequence gene. address issue prevalence most frequently observed control population, examined 400 healthy white subjects 272C>T...
Abstract Background Lymphoblastic lymphoma (LBL) is the second most frequent subtype in childhood. It commonly treated according to therapy strategies for lymphoblastic leukemia. Methods The AIEOP LNH‐92 protocol was a modified LSA2‐L2 used both T‐ and B‐cell precursor LBL included Induction, Consolidation, Maintenance treatment with total duration of 11 24 months stages I II, III IV disease, respectively. Results Fifty‐five eligible patients were enrolled, 40 males 15 females, median age 8...
Purpose To study minimal disseminated disease (MDD) in children with Burkitt's lymphoma (BL) and to determine its impact on prognosis. Patients Methods We established a simplified long-distance polymerase chain reaction (LD-PCR) assay that can amplify up 15 20 Kb of DNA sequence, making it possible detect the t(8;14) at genomic level sensitivity 10 −4 . prospectively studied diagnostic biopsies bone marrow aspirates from 134 patients affected by BL. Results A specific LD-PCR product was...
Abstract Background Anaplastic large cell lymphoma (ALCL) represents approximately 15% of all pediatric non‐Hodgkin lymphomas (NHL). It has distinct clinical features, including frequent involvement extranodal sites and rare localization to the central nervous system (CNS). Despite varying treatment approaches outcome patients with ALCL not significantly improved during last two decades. Procedure From October 1997 beginning 2000, newly diagnosed were enrolled into AIEOP LNH‐97 protocol for...
Background The use of intensive chemotherapy regimens in children with lymphoblastic lymphoma (LBL) has significantly improved outcome, but the salvage rate for these patients is still poor. aim this study was to evaluate prognostic value minimal disseminated disease (MDD), studied by multiparametric flow cytometry (MFC), pediatric T‐ and B‐lineage LBL. Procedure We examined bone marrow (BM) peripheral blood (PB) samples from a series 65 affected (52) (13) LBL using an MFC method; 10 them...